BioSpace News Archive

Zura Bio Limited a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Omega Therapeutics, Inc. announced the presentation of new preclinical data from two different programs that demonstrated sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation, respectively, at the American Association for the Study of Liver Diseases’ The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.

Acumen Pharmaceuticals, Inc. reported financial results for the third quarter of 2023 and provided a business update.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced top-line results from a Phase 2b study of zunsemetinib, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.

Bio-Techne Corporation announced that it will present at the following investor conferences.

Abeona Therapeutics Inc. reported financial results for the third quarter of 2023 and provided corporate updates.

Cognito Therapeutics today announced that Brent Vaughan, Chief Executive Officer, will present at the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023 in New York, NY.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® technology platform, today reported financial results for the third quarter ended September 30, 2023.

LIXTE Biotechnology Holdings, Inc. chemotherapy and immunotherapy benefit, today provided an update on its progress.

Inogen, Inc. today announced that its Board of Directors has appointed Kevin Smith as Inogen’s President and Chief Executive Officer and a member of the Board of Directors, effective immediately, succeeding Nabil Shabshab.